Nurix secures a transformative Roche partnership, gaining $700M upfront, 50% U.S. profit share, and

BRISBANE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clini

Nurix Therapeutics, Inc. (NASDAQ: NRIX - Get Free Report)'s stock price hit a new 52-week high durin

RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform a

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the d

Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has ea

Phase 3 trial designed to demonstrate superiority of bexobrutideg versus pirtobrutinib in patients w

Morgan Stanley analyst Terence Flynn maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight

RHHBY posts 6% constant-currency sales growth in the first half of 2026 as strong demand for key dru

UBS analyst David Dai maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price

Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is

Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is

Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is

BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clini

Amova Asset Management Americas Inc. cut its position in shares of Nurix Therapeutics, Inc. (NASDAQ:

Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by

Mizuho analyst Joseph Catanzaro maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and

Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and

RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform a

Stifel analyst Stephen Willey maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises th

BTIG analyst Jeet Mukherjee reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains

HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Bu

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.81 per share versus the Zacks C

Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.81) per share which missed the ana

Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up t

Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a lik

The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 29.2% upside in the st

Health care stocks flashing warning to momentum investors. RSI indicator shows overbought for DFTX,

NRIX rallies on its collaboration with Roche for bexobrutideg, featuring a $700 million upfront paym

Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher

Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday'

Baird analyst Joel Beatty maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises

Recently, Nurix secured a partnership with Roche, which I believe has substantially derisked the sto

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the di

High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor

HC Wainwright & Co. analyst Robert Burns reiterates Nurix Therapeutics (NASDAQ:NRIX) with a B

Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and

Nurix Therapeutics, Inc. remains a Strong Buy as bexobrutideg advances in pivotal r/r CLL trials and

Wall Street analysts change outlook on top names. B of A cuts CPB, UBS cuts AJG PT, B of A boosts OR

Nurix Therapeutics (NRIX) was a big mover last session on higher-than-average trading volume. The la

BTIG analyst Jeet Mukherjee maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the

Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercializat

Jefferies analyst Roger Song maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the

Needham analyst Gil Blum maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the pri

Nurix Therapeutics and Roche sign a BTK degrader partnership worth up to $2.3 billion, supporting Ph

href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in

Agreement offers potential best-in-class targeted protein degrader therapy option for people living

BTIG analyst Jeet Mukherjee reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains

HC Wainwright & Co. analyst Robert Burns reiterates Nurix Therapeutics (NASDAQ:NRIX) with a B